Skip to search formSkip to main contentSkip to account menu

American Society of Clinical Oncology

Known as: ASCO 
The world's leading professional organization representing physicians of all oncology disciplines and subspecialties. ASCO sets the standard for… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
1. OVERVIEW: GENERAL PRINCIPLES FOR ALL ASCO GUIDELINE PRODUCTS ( e.g. de novo, Update, Endorsement, Adaptation, Provisional… 
Highly Cited
2014
Highly Cited
2014
1005 Background: We previously showed in participants with TNBC of the neoadjuvant phase II GeparSixto study (NCT01426880) that… 
Highly Cited
2010
Highly Cited
2010
4010 Background: In a randomized phase II trial of F vs G in 88 MPA patients (pts), we reported that F induces a response rate… 
Highly Cited
2009
Highly Cited
2009
LBA6006 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings… 
Review
2006
Review
2006
LBA3 Background: Two multicenter phase II trials of 2nd line monotherapy with sunitinib (SU11248) in patients (pts) with mRCC… 
Highly Cited
2005
Highly Cited
2005
7058 Background: Significant pneumonitis (≥ grade 3) is reported in up to 19% of patients (pts) with stage III non-small cell… 
Highly Cited
2004
Highly Cited
2004
4006 BACKGROUND: DX is a novel hexacyclic, water-soluble, topoisomerase-1 inhibitor. DX has single-agent and combination activity… 
2004
2004
Scott M. Lippman and Bernard Levin, The University of Texas M. D. Anderson Cancer Center, Houston, TX; Dean E. Brenner… 
Highly Cited
2004
Highly Cited
2004
4020 Background: ECF is currently considered by many as a standard regimen in AGC in Europe. Based on the high efficacy reported… 
Review
1996
Review
1996
PURPOSE Dissemination of use of the hematopoietic colony-stimulating factors (CSFs) is unprecedented in oncology, with almost all…